Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | IDE | P14735 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7280901 | 0.90 | REN (0.47) | RENCYP3A4CYP2D6TBXAS1CYP1A2 | |
| SCHEMBL6976760 | 0.90 | REN (0.47) | RENCYP3A4CYP2D6TBXAS1CYP1A2 | |
| SCHEMBL7426636 | 0.79 | HRH4 (0.53) | RENCYP3A4CYP2D6TBXAS1CYP1A2 | |
| SCHEMBL7426640 | 0.74 | CYP1A2 (0.44) | CYP3A4CYP2D6TBXAS1CYP1A2CYP2C9 | |
| SCHEMBL7298846 | 0.72 | REN (0.46) | RENCYP1A2 | |
| SCHEMBL6952096 | 0.72 | REN (0.49) | REN | |
| SCHEMBL9432392 | 0.71 | EGLN3 (0.47) | HTTIDETBXAS1 | |
| SCHEMBL7302265 | 0.69 | ANPEP (0.49) | RENCYP3A4CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL7303707 | 0.68 | SIGMAR1 (0.51) | CYP1A2 | |
| SCHEMBL7326577 | 0.68 | SIGMAR1 (0.51) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087801-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | G.D. SEARLE & CO. | 2004-05-06 | — | — | US | disclosed |
| US-20030130329-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | G.D. SEARLE & CO. | 2003-07-10 | — | — | US | disclosed |
| US-20020115867-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | HANSON GUNNAR J (US) | 2002-08-22 | — | — | US | disclosed |
| EP-0655059-B1 | IMIDAZOLYL/BENZIMIDAZOLYL-TERMINATED ALKYLAMINO ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1994004508-A1 | IMIDAZOLYL/BENZIMIDAZOLYL-TERMINATED ALKYLAMINO ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087801-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | REN, AGTR1, AGTR2 | REN 1/4885HTT 4140/4885CYP3A4 245/4885 |
| US-20020115867-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | REN, AGT, AGTR1 | REN 1/4885HTT 4147/4885CYP3A4 174/4885 |
| US-20030130329-A1 | Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension | REN, AGTR1, AGTR2 | REN 1/4885HTT 4140/4885CYP3A4 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.